Administer modified Ankara virus vaccine (Jynneos™️). Pre-exposure vaccination: 0.5 mL subcutaneous dose with a 2-dose schedule, 28-day interval to laboratory personnel handling samples for MPX dg. Post-exposure vaccination: single dose (0.5 mL) subcutaneously to close contacts of confirmed cases older than 18 years (skin-to-skin) prioritizing those at risk of severe disease (immunocompromised), ideally within 4 days and up to 14 days if asymptomatic. In case the epidemiological scenario requires it, it is recommended to administer the fractionated vaccine (0.1 mL) intradermally, either as an initial scheme or for complementary doses. For cases outside the above-mentioned indications, a case-by-case analysis will be made on a case-by-case basis and with consultation.